Calithera Biosciences, Inc.
DelistedCIK 1496671fmd_19405BMD5ZSFFSD0D1CMA32X2CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Dec 31, 2022, 39 periods
Latest annual · FY2021
Millions- Total revenues
- 10
- Operating income
- (42)
- Net income
- (40)
- Free cash flow
- (44)
Latest quarter · Q4 FY2022
Millions- Operating income
- (7)
- Net income
- (7)
- Free cash flow
- (9)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2018 to FY2021
- -24.0%
- Net income, 5 yearsFY2017 to FY2022
- n/m
Calithera Biosciences, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$42.1 million | -$115.4 million | 10-K 2023-03-31 · proof | |
| Net income | -$39.7 million | -$115.1 million | 10-K 2023-03-31 · proof | |
| Cash from operating activities | -$43.6 million | -$66.3 million | 10-K 2023-03-31 · proof | |
| Free cash flow | -$43.7 million | -$66.4 million | 10-K 2023-03-31 · proof | |
| Total assets | $28.7 million | $64.8 million | -55.7% | 10-K 2023-03-31 · proof |
| Total liabilities | $8.3 million | $15.7 million | -47.1% | 10-K 2023-03-31 · proof |
| Cash and cash equivalents | $25.5 million | $59.5 million | -57.3% | 10-K 2023-03-31 · proof |
- What was Calithera Biosciences, Inc.'s operating income in fiscal 2022?
- Calithera Biosciences, Inc. reported operating income of -$42.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$115.4 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What was Calithera Biosciences, Inc.'s net income in fiscal 2022?
- Calithera Biosciences, Inc. reported net income of -$39.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$115.1 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What was Calithera Biosciences, Inc.'s cash from operating activities in fiscal 2022?
- Calithera Biosciences, Inc. reported cash from operating activities of -$43.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$66.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What was Calithera Biosciences, Inc.'s free cash flow in fiscal 2022?
- Calithera Biosciences, Inc. reported free cash flow of -$43.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$66.4 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Calithera Biosciences, Inc.'s total assets?
- As of Dec 31, 2022, Calithera Biosciences, Inc. reported total assets of $28.7 million, against $64.8 million a year earlier (-55.7%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Calithera Biosciences, Inc.'s total liabilities?
- As of Dec 31, 2022, Calithera Biosciences, Inc. reported total liabilities of $8.3 million, against $15.7 million a year earlier (-47.1%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Calithera Biosciences, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Calithera Biosciences, Inc. reported cash and cash equivalents of $25.5 million, against $59.5 million a year earlier (-57.3%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1496671&period_type=annual&limit=5"Information only, not investment advice.